Ultrahigh-Field MR (7 T) Imaging of Brain Lesions in Neuromyelitis Optica

Kister, Ilya; Herbert, Joseph; Zhou, Yongxia; Ge, Yulin

doi:10.1155/2013/398259

Cited by 59 publications

(70 citation statements)

References 32 publications

(45 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The 'central vein sign' (CVS) has been investigated in various neurological conditions by several groups, and evidence has accumulated that the CVS may have the ability to accurately differentiate MS from its mimics [15][16][17][18][19][20][21] . As a consequence, recent guidelines from the Magnetic Resonance Imaging in MS (MAGNIMS) group 1,4 and the Consortium of MS Centers (CMSC) task force 22 have acknowledged the potential of the CVS and its dedicated MRI acquisitions for the differential diagnosis of MS, while calling for further research before considering a possible modification of the diagnostic criteria.…”

mentioning

confidence: 99%

The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative

et al. 2016

View full text Add to dashboard Cite

At present, the diagnosis of multiple sclerosis (MS) relies heavily on the use of MRI, which can demonstrate disease dissemination in space and time [1][2][3][4] . The current 2010 McDonald criteria have enabled earlier diagnosis 5,6 and initiation of disease-modifying treatment, with substantial benefits for disease outcome 7,8 , but they still have imperfect sensitivity and specificity 9,10 . The limited accuracy of the criteria results in challenging cases and misdiagnosis, which are prevalent problems in MS 11,12 . Therefore, more-accurate and pathologically specific MRI criteria are still needed to exclude other disorders that can mimic MS 13,14 .The MRI-detectable central vein inside white matter lesions has recently been proposed as a biomarker of inflammatory demyelination and, thus, may aid the diagnosis of MS 15 . The 'central vein sign' (CVS) has been investigated in various neurological conditions by several groups, and evidence has accumulated that the CVS may have the ability to accurately differentiate MS from its mimics [15][16][17][18][19][20][21] . As a consequence, recent guidelines from the Magnetic Resonance Imaging in MS (MAGNIMS) group 1,4 and the Consortium of MS Centers (CMSC) task force 22 have acknowledged the potential of the CVS and its dedicated MRI acquisitions for the differential diagnosis of MS, while calling for further research before considering a possible modification of the diagnostic criteria. However, the lack of standardization for the definition and imaging of the CVS, as well as a dearth of large-scale prospective studies evaluating the CVS for MS diagnosis, are currently preventing the clinical validation of this potential biomarker 1,23 .This Consensus Statement aims to provide recommendations for the definition, standardization and clinical evaluation of the CVS in the diagnosis of MS. These statements are based on a thorough review of the existing literature on the CVS and the consensus opinion of the members of the North American Imaging in Multiple Sclerosis (NAIMS) Cooperative. E X P E RT C O N S E N S U S D O C U M E N T on behalf of the NAIMS CooperativeAbstract | Over the past few years, MRI has become an indispensable tool for diagnosing multiple sclerosis (MS). However, the current MRI criteria for MS diagnosis have imperfect sensitivity and specificity. The central vein sign (CVS) has recently been proposed as a novel MRI biomarker to improve the accuracy and speed of MS diagnosis. Evidence indicates that the presence of the CVS in individual lesions can accurately differentiate MS from other diseases that mimic this condition. However, the predictive value of the CVS for the development of clinical MS in patients with suspected demyelinating disease is still unknown. Moreover, the lack of standardization for the definition and imaging of the CVS currently limits its clinical implementation and validation. On the basis of a thorough review of the existing literature on the CVS and the consensus opinion of the members of the North American Imaging in Mult...

show abstract

mentioning

confidence: 99%

The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative

et al. 2016

View full text Add to dashboard Cite

show abstract

“…66 Cortical pathology correlates better with cognitive and motor parameters than white matter T2 lesion burden in MS, 67 55 found no cortical lesions in 10 patients with NMO spectrum disorder studied with ultrahigh-field (7T); of 92 white matter lesions studied, only 8 were traversed by a central venule, a further distinction from MS that indicates a fundamental dichotomy in the pathogenesis of the 2 conditions. Voxel-based morphometry has been used to compare gray matter structures in NMO, MS, and healthy controls.…”

Section: Cortical and Deep Gray Matter Pathologymentioning

confidence: 99%

“…The recent application of advanced imaging techniques to NMO, including ultra-high-field MR imaging (7T), 55 Table).…”

Section: Advanced Mr Imagingmentioning

confidence: 99%

Conventional and Advanced Imaging in Neuromyelitis Optica

Barnett

Sutton

Ghadiri

et al. 2013

American Journal of Neuroradiology

View full text Add to dashboard Cite

SUMMARY:Myelitis and optic neuritis are prototypic clinical presentations of both multiple sclerosis and neuromyelitis optica. Once considered a subtype of multiple sclerosis, neuromyelitis optica, is now known to have a discrete pathogenesis in which antibodies to the water channel, aquaporin 4, play a critical role. Timely differentiation of neuromyelitis optica from MS is imperative, determining both prognosis and treatment strategy. Early, aggressive immunosuppression is required to prevent the accrual of severe disability in neuromyelitis optica; conversely, MS-specific therapies may exacerbate the disease. The diagnosis of neuromyelitis optica requires the integration of clinical, MR imaging, and laboratory data, but current criteria are insensitive and exclude patients with limited clinical syndromes. Failure to recognize the expanding spectrum of cerebral MR imaging patterns associated with aquaporin 4 antibody seropositivity adds to diagnostic uncertainty in some patients. We present the state of the art in conventional and nonconventional MR imaging in neuromyelitis optica and review the place of neuroimaging in the diagnosis, management, and research of the condition. ABBREVIATIONS: AQP4 ϭ aquaporin 4; LESCL ϭ longitudinally extensive spinal cord lesion; MT ϭ magnetization transfer; NMO ϭ neuromyelitis optica

show abstract

“…Zudem können, wie im späteren Abschnitt "Neuromyelitis-opticaErkrankungsspektrum" beschrieben, KL nicht bei allen neuroimmunologischen Krankheitsbildern beobachtet werden [54,99], woraus sich eine potenzielle differentialdiagnostische Relevanz der KL ableiten lässt. …”

Section: Läsionen Der Grauen Hirnsubstanzunclassified